Envista Holdings Corp NVST
We take great care to ensure that the data presented and summarized in this overview for Envista Holdings Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVST
View all-
Black Rock Inc. New York, NY19.5MShares$339 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA17.3MShares$301 Million0.01% of portfolio
-
Morgan Stanley New York, NY13.9MShares$243 Million0.02% of portfolio
-
Harris Associates L P Chicago, IL10.8MShares$188 Million0.31% of portfolio
-
Atlanta Capital Management CO L L C Atlanta, GA10.5MShares$183 Million1.53% of portfolio
-
Ariel Investments, LLC Chicago, IL9.87MShares$172 Million1.94% of portfolio
-
Nuance Investments, LLC Kansas City, MO7.04MShares$123 Million4.04% of portfolio
-
Gates Capital Management, Inc. New York, NY6.87MShares$120 Million2.75% of portfolio
-
American Century Companies Inc Kansas City, MO6.73MShares$117 Million0.07% of portfolio
-
Dimensional Fund Advisors LP Austin, TX6.1MShares$106 Million0.03% of portfolio
Latest Institutional Activity in NVST
Top Purchases
Top Sells
About NVST
Envista Holdings Corporation, together with its subsidiaries, engages in the development, sale, and marketing of dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, and Orascoptic brands; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Insignia, AOA, and Spark brands. This segment also offers software packages, which include DTX Studio Implant for treatment planning of dental implants; TX Studio Lab for prosthetics treatment planning; and DTX Studio Clinic to store and access a various clinical patient images. The company's Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, sensors, software, and other visualization/magnification systems; endodontic systems and related consumables; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
Insider Transactions at NVST
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 25
2024
|
Robert Befidi President, Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
3,454
-7.99%
|
$62,172
$18.7 P/Share
|
Aug 25
2024
|
Eric D. Hammes Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
64,175
+41.98%
|
-
|
Aug 13
2024
|
Paul A Keel Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+6.93%
|
$480,000
$16.87 P/Share
|
Aug 12
2024
|
Eric D. Hammes Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
24,532
+50.0%
|
$392,512
$16.33 P/Share
|
Jul 15
2024
|
Mark E Nance General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
491
-0.85%
|
$7,365
$15.94 P/Share
|
Jun 25
2024
|
Stephen Keller Principal Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+36.74%
|
-
|
May 25
2024
|
Paul A Keel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
372,605
+47.36%
|
-
|
May 25
2024
|
Eric Conley SVP, Orthodontics |
SELL
Payment of exercise price or tax liability
|
Direct |
642
-1.19%
|
$11,556
$18.25 P/Share
|
May 21
2024
|
Christine A Tsingos Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,085
+20.08%
|
-
|
May 21
2024
|
Vivek Jain Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,085
+23.32%
|
-
|
May 21
2024
|
R Scott Huennekens Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,170
+20.44%
|
-
|
May 21
2024
|
Barbara B. Hulit Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,085
+12.69%
|
-
|
May 21
2024
|
Daniel Raskas Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,085
+22.76%
|
-
|
May 21
2024
|
Wendy Carruthers Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,085
+20.07%
|
-
|
May 21
2024
|
Kieran Gallahue Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,085
+22.76%
|
-
|
Apr 15
2024
|
Barbara B. Hulit Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,065
+18.06%
|
-
|
Mar 15
2024
|
Barbara B. Hulit Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,705
+20.21%
|
-
|
Feb 25
2024
|
Amir Aghdaei Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,570
+13.52%
|
-
|
Feb 25
2024
|
Amir Aghdaei Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
33,367
-11.3%
|
$734,074
$22.65 P/Share
|
Feb 25
2024
|
Eric Conley SVP, Orthodontics |
BUY
Grant, award, or other acquisition
|
Direct |
7,730
+12.55%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 735K shares |
---|---|
Open market or private purchase | 73.7K shares |
Payment of exercise price or tax liability | 71.4K shares |
---|